U.S. markets closed

Seres Therapeutics, Inc. (MCRB)

NasdaqGS - NasdaqGS Real Time Price. Currency in USD
Add to watchlist
25.65-1.21 (-4.50%)
At close: 4:00PM EDT
Full screen
Trade prices are not sourced from all markets
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Bearishpattern detected
Relative Strength Index (RSI)

Relative Strength Index (RSI)

Previous Close26.86
Open26.16
Bid25.55 x 800
Ask25.70 x 800
Day's Range24.26 - 26.24
52 Week Range2.52 - 33.00
Volume2,265,886
Avg. Volume3,011,422
Market Cap2.29B
Beta (5Y Monthly)4.48
PE Ratio (TTM)N/A
EPS (TTM)-1.07
Earnings DateJul 28, 2020
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est33.36
Fair Value is the appropriate price for the shares of a company, based on its earnings and growth rate also interpreted as when P/E Ratio = Growth Rate. Estimated return represents the projected annual return you might expect after purchasing shares in the company and holding them over the default time horizon of 5 years, based on the EPS growth rate that we have projected.
Fair Value
XX.XX
Overvalued
Research that delivers an independent perspective, consistent methodology and actionable insight
Related Research
View more
  • Seres Therapeutics to Present at Upcoming Investor Conferences
    Business Wire

    Seres Therapeutics to Present at Upcoming Investor Conferences

    Seres Therapeutics, Inc. (Nasdaq:MCRB) today announced that management will present at two upcoming investor conferences:

  • Seres Therapeutics Announces U.S. Food and Drug Administration Correspondence Following Positive SER-109 Phase 3 Study Results
    Business Wire

    Seres Therapeutics Announces U.S. Food and Drug Administration Correspondence Following Positive SER-109 Phase 3 Study Results

    Seres Therapeutics, Inc. (Nasdaq: MCRB) today announced that it has obtained correspondence from the Office of Vaccines Research and Review of the U.S. Food and Drug Administration (FDA) regarding the Company’s plans to submit a Biologics License Application (BLA) to support product approval of SER-109 for recurrent C. difficile infection (CDI). After obtaining highly statistically significant topline Phase 3 ECOSPOR III SER-109 study results in recurrent CDI, Seres requested a Breakthrough Therapy Designation meeting with the FDA. In response to the meeting request, the FDA reaffirmed its prior guidance regarding the efficacy requirements to support a SER-109 BLA submission, which were exceeded by the recent positive SER-109 Phase 3 study results, reaffirmed its prior guidance that at least 300 patients will be required for the safety database, and indicated there was not a reason for a meeting at this time.

  • The Seres Therapeutics (NASDAQ:MCRB) Share Price Has Soared 590%, Delighting Many Shareholders
    Simply Wall St.

    The Seres Therapeutics (NASDAQ:MCRB) Share Price Has Soared 590%, Delighting Many Shareholders

    While stock picking isn't easy, for those willing to persist and learn, it is possible to buy shares in great...